AIM
ARCT icon

Acrospire Investment Management’s Arcturus Therapeutics ARCT Stock Holding History

Acrospire Investment Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-424
Closed -$3K – 92
2017
Q2 		$3K Sell
424
-2,860
-87% -$23K ﹤0.01% 2014
2017
Q1 		$26K Buy
3,284
+2,931
+830% +$27.1K 0.02% 1447
2016
Q4 		$5K Buy
+353
New +$5.28K ﹤0.01% 2046

Other funds holding ARCT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
LCM
Leisure Capital Management Costa Mesa, California $320M AUM 39.11% 1-Year Est. Return

Acrospire Investment Management's ARCT Position: Q3 2017 in Review

Acrospire Investment Management sold out of Arcturus Therapeutics (ARCT) in Q3 2017, closing a stake of 424 shares — an estimated $3K sold.

Acrospire Investment Management first reported a position in ARCT in Q4 2016 and held it in 3 quarters. The position peaked at $26K in Q1 2017. 24 funds tracked by Wall St. Rank hold ARCT as of Q3 2017.

  • Acrospire Investment Management reported no remaining Arcturus Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 424 Arcturus Therapeutics shares in Q3 2017, an estimated $3K.
  • Acrospire Investment Management first reported a position in Arcturus Therapeutics in Q4 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Arcturus Therapeutics position peaked at $26K in Q1 2017.
  • 24 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.